ProChon Biotech Ltd. touted the results of a study on knee cartilage defect patients treated with its BioCart system.
Thirty-one Israeli patients received the arthroscopically administered treatment to correct a single full-thickness cartilage defect in the femoral condyle, according to the company. The BioCart autologous cartilage system uses proprietary fibroblast growth factor technology to help regenerate damaged cartilage.
The Woburn, Mass.-based company demonstrated the patients’ improvement, who were recruited six to 49 months after the implant surgery, through scoring on the International Knee Documentation Committee knee evaluation form and MRI mapping, according to a press release.
In March, the company said it hoped to complete enrollment for its U.S. and Israel based "Phase II" clinical study by June of 2010, but CEO Patrick O’Donnell said the study is now entering the "final stages" of patient enrollment, which the company anticipates "completing early in the 2010 fourth quarter."
BioCart is only available commercially in Israel.